Durable remission of locally advanced breast cancer with multimodality management

A. Miller, P. Khosla, J. Lynch, J. Moreb, S. Cullins, H. Safah, C. Hutchison, V. La Russa, K. Vellis, J. Rice, N. Mendenhall, R. Weiner

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


We treated 20 women with locally advanced breast cancer between January 1991 and September 1996. The treatment regimen included 4 cycles of intensive doxorubicin (30 mg/m2/d on 3 consecutive days every 2 weeks with G-CSF support), followed by appropriate surgery, followed by high dose therapy with cyclophosphamide, carboplatin and thiotepa (STAMP V, CTCb). Of the 20 patients, seven presented with inflammatory breast cancer, three with Stage IIIB, seven with stage IIIA, one with multifocal Stage IIB and two with Stage IV M1 (ipsilateral supraclavicular lymph node involvement) (including one who had an inflammatory primary) disease. Six patients had not undergone mastectomy at the time of entering the protocol. These six received the doxorubicin in a neoadjuvant fashion and were thus evaluable for tumor response. The remaining 14 received doxorubicin as adjuvant therapy prior to intensification and transplantation. All patients underwent local-regional radiation therapy and were placed on oral tamoxifen. Doxorubicin was well tolerated in this schedule with all but three patients receiving all their cycles on schedule. Both BM and PBPC were easily collected after this regimen and, when reinfused, resulted in the prompt recovery of granulocytes (median 11 days to 500 absolute granulocyte count) and platelets (median 13 days of 20 000 platelets). The six patients who received doxorubicin prior to mastectomy all had major clinical responses, but were found to have microscopic focii of breast cancer in the mastectomy specimens. The overall treatment was well tolerated with the exception of one treatment-related death (5%). The overall and relapse free survival are 70% and 58% respectively with a median follow-up of 40 months (range 12-74 months). When the Stage IV patients are censored, the relapse-free survival rate is 69%. In the bone marrow transplant phase of treatment, the major non-hematologic toxicities were stomatitis (70%) and anorexia requiring parental nutrition (75%).

Original languageEnglish (US)
Pages (from-to)89-95
Number of pages7
JournalMedical Oncology
Issue number2
StatePublished - Jul 1998


  • Bone marrow transplantation
  • Breast cancer
  • Hematopoietic stem cell transplantation
  • Locally advanced
  • Multimodality treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Durable remission of locally advanced breast cancer with multimodality management'. Together they form a unique fingerprint.

Cite this